GCEIP 500 Global rank #122 · Switzerland
CRISPR Therapeutics: biotechnology and the business behind its reach
CRISPR Therapeutics develops gene-editing medicines using CRISPR/Cas9 technology.
The company
What it does
CRISPR Therapeutics operates in biotechnology. Its business model, products and customers connect it to a wider market, with the company’s own disclosures providing the basis for understanding its activities and reach.
Across markets
The company’s research explores treatments for serious diseases, including blood disorders and cancer. Gene-editing therapies may offer new options, but their benefit, risks, durability and access must be evaluated through clinical evidence and long-term follow-up.
The company’s footprint and context are linked to the public sources below.
GCEIP view
What the record tells us
GCEIP sees the company’s importance in translating a laboratory tool into potential treatments. The distinction between scientific promise and demonstrated patient benefit remains essential in assessing its impact.
Published recognition
Selected results
See published awards and company-list results 1 sources
- TIME100 Most Influential Companies · 2025View source
TIME100 Companies selection
Named by TIME editors among 105 businesses for company-specific influence, impact, innovation, ambition or success; analysis of the specific business case pending